Adam Rynerson joined Solomon Partners in 2021 and is an Associate in Healthcare .
Over the years, Adam has advised boards of directors and special committees as well as companies on a broad range of transactions, including mergers, acquisitions, divestitures, and capital raising solutions.
Most recently, Adam advised pharmacy benefit manager Prime Therapeutics on its acquisition of Magellan Rx from Centene Corporation and healthcare analytics platform Panalgo on its sale to Welsh Carson and Hg-backed MMIT.
Prior to joining Solomon, Adam was an Associate at Houlihan Lokey.
Adam holds a Bachelor of Science in Finance from Indiana University, Kelley School of Business.
Serving as the exclusive financial advisor and placement agent to Prime Therapeutics on its pending acquisition of Magellan Rx
Served as exclusive financial advisor to Panalgo on its sale to MMIT & Evaluate, a Welsh, Carson, Anderson & Stowe and Hg portfolio company